Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial

Lee, Yang-Cheng; Huang, Wen-Tsung; Lee, Ming-Yang; Tsao, Chao‐Jung; Feng, Yin‐Hsun

doi:10.21873/invivo.13099

Cited by 11 publications

(9 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Survival rate at 6 months was 76%, comparable to 84.8% survival achieved in the trial 1 . In addition, the results of our study are comparable to those of other recent real‐world studies on the use of atezolizumab–bevacizumab as first‐line treatment for HCC, 8–10 and to studies including patients receiving atezolizumab–bevacizumab in the post‐first‐line setting 11 …”

Section: Discussionsupporting

confidence: 87%

“…In the IMbrave150 trial, only 69% (501/725) of screened patients were included in the intention-to-treat analysis, 1 In addition, the results of our study are comparable to those of other recent real-world studies on the use of atezolizumab-bevacizumab as first-line treatment for HCC, [8][9][10] and to studies including patients receiving atezolizumab-bevacizumab in the post-first-line setting. 11 The efficacy of atezolizumab-bevacizumab in our cohort may be attributed to the predominantly Asian patient cohort. Recent randomized clinical trials suggested a greater survival benefit for ICIs among Asian populations.…”

Section: Discussionmentioning

confidence: 83%

See 1 more Smart Citation

Real‐world experiences of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma in Hong Kong

Yiu,

Chan,

Wong

et al. 2023

Liver Cancer International

View full text Add to dashboard Cite

Background and AimsThe IMbrave150 trial established atezolizumab–bevacizumab as the new standard of care for hepatocellular carcinoma (HCC). However, evidence on its applications in real‐world patients is limited. We report the efficacy and safety of atezolizumab–bevacizumab in a Chinese cohort of HCC patients ineligible for clinical trials.MethodsElectronic medical records of patients diagnosed with HCC and with pharmacy orders of atezolizumab and bevacizumab between 2019 and 2021 were retrospectively reviewed. Patients' demographics, performance status, stage, treatment received, adverse events and death time (if any) were recorded.ResultsThirteen eligible patients were included. mOS of HCC patients was 18.6 months [6.8–30.4], while mPFS was 9.3 months [0–19.4]. No grade 5 adverse events were reported.ConclusionsThis real‐world study provides real‐world experiences of atezolizumab–bevacizumab as first‐line and subsequent therapy in patients with unresectable HCC. Further validation on the efficacy and safety of atezolizumab–bevacizumab as second‐line or later lines of treatment should be conducted.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 83%

Real‐world experiences of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma in Hong Kong

Yiu,

Chan,

Wong

et al. 2023

Liver Cancer International

View full text Add to dashboard Cite

show abstract

“…Atezo-Bev exerts immune-modulatory effects by blocking PD-1/PD-L1 pathways and inhibiting neovascularization by suppressing the action of VEGF. Several real-world studies reported after the IMbrave 150 trial have verified the robust efficacy and favorable safety profile of using these therapies in combination for advanced HCC 9–12 . However, using Atezo-Bev is not without risks, as both individual drugs have specific considerations that can impact survival regardless of an antitumor response.…”

Section: Discussionmentioning

confidence: 99%

Predictors of Survival in Patients With Hepatocellular Cancer Receiving Atezolizumab and Bevacizumab

Ledenko,

Mercado,

Patel

2023

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Objectives: In randomized clinical trials in patients with hepatocellular cancer (HCC), combination therapy with atezolizumab and bevacizumab (Atezo-Bev) prolonged survival, and these treatments have become the standard first-line therapy for advanced HCC. However, clinical trials may not reflect real-life clinical practice due to treatment selection criteria. Thus, our aim was to understand predictors of HCC outcomes with these treatments in a real-world, multicenter setting. Methods: A retrospective review of all patients 18 years of age or older treated for advanced primary liver cancer between February 2020 and August 2022 was conducted to assess the relationship between overall survival and clinical and biochemical variables before or during treatment. Univariate and multivariate Cox regression survival analyses were performed to identify predictors of survival following treatment. Results: One hundred and eleven eligible patients with unresectable HCC received Atezo-Bev over a consecutive 30-month period. Cox regression identified several significant (P<0.05) predictors of survival, including pretreatment albumin (hazard ratios [HR]: 0.2; CI: 0.1-0.4), total bilirubin (HR: 1.3; CI: 1.2-1.5), and international normalized ratio (HR: 5.6; CI: 2.5-12.5). In multivariate analyses, these were significantly associated as predictors of mortality, and patients with pretreatment albumin <3.5 mg/dL had significantly lower survival than those ≥3.5 (153 vs. 522 d, P<0.0001). Conclusions: Pretreatment hypoalbuminemia, high bilirubin, and biochemical tests indicative of hepatic or renal dysfunction can independently predict short-term mortality in advanced HCC patients receiving Atezo-Bev.

show abstract

“…Recent research has demonstrated that combination treatment with BEV induces significant transcriptional changes that impact glioblastoma [ 32 ]. In Taiwan, bevacizumab has achieved certain success in the treatment of various cancers, including breast cancer [ 33 ], colorectal cancer [ 34 – 37 ], non-small cell lung cancer [ 38 ], and liver cancer [ 39 ]. According to clinical trials and case reports, bevacizumab has been shown to prolong progression-free survival (PFS), reduce tumor size, improve quality of life, and extend overall survival (OS).…”

Section: Discussionmentioning

confidence: 99%

Polymorphism at codon 31 of CDKN1A (p21) as a predictive factor for bevacizumab therapy in glioblastoma multiforme

Cheng,

Shen,

Liang

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Glioblastoma (GBM), a prevalent and malignant brain tumor, poses a challenge in surgical resection due to its invasive nature within the brain parenchyma. CDKN1A (p21, Waf-1), a cyclin-dependent kinase inhibitor, plays a pivotal role in regulating cell growth arrest, terminal differentiation, and apoptosis. The existence of natural variants of CDKN1A has been associated with specific cancer types. In this retrospective study, our objective was to identify polymorphic variants of CDKN1A, specifically c.93C > A (codon 31 Ser31Arg), and investigate its potential impact within the scope of bevacizumab therapy for glioblastoma multiforme. This study involved a cohort of 139 unrelated adult Chinese GBM patients in Taiwan. Genomic DNA extracted from tumor samples was utilized for genotyping using the polymerase chain reaction (PCR) restriction fragment length polymorphism method (PCR–RFLP analysis). Through unconditional logistic regression analysis, odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated. Our findings unveiled that among these GBM patients, the distribution of codon 31 polymorphisms was as follows: 23.02% were Serine homozygotes (Ser/Ser), 27.34% were Arginine homozygotes (Arg/Arg), and 49.64% were Serine/Arginine heterozygotes (Ser/Arg). While CDKN1A c.93C > A polymorphisms did not exhibit a direct association with overall survival in GBM patients, noteworthy survival benefits emerged among individuals with Arg/Arg and Arg/Ser genotypes who received combined concurrent chemoradiotherapy (CCRT) and bevacizumab treatment compared to those who underwent CCRT alone. Our findings indicate a significant involvement of the CDKN1A c.93C > A polymorphism in the development and onset of GBM, offering potential implications for the early prognostication of bevacizumab therapy outcomes.

show abstract

Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial

Cited by 11 publications

References 17 publications

Real‐world experiences of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma in Hong Kong

Real‐world experiences of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma in Hong Kong

Predictors of Survival in Patients With Hepatocellular Cancer Receiving Atezolizumab and Bevacizumab

Polymorphism at codon 31 of CDKN1A (p21) as a predictive factor for bevacizumab therapy in glioblastoma multiforme

Contact Info

Product

Resources

About